Advanced Life Sciences Holdings Inc
Advanced Life Sciences — Investor Presentation (September 2007)
29 slides from Advanced Life Sciences's investor presentation, Sep 26, 2007
Slide 1: Advanced Life Sciences - Advancing Discoveries For Health
¢ § 2 ow ADVANCED IFE SCIENCES % Advancing Discoveries For Health NASDAQ: ADLS >
Slide 2: Safe Harbor Statement
2 Safe Harbor Statement This presentation contains forward-looking statements about Advanced Life Sciences Holdings, Inc., including statements regarding the clinical trials and regulatory pathway of cethromycin. Forward-looking statements represent our management’s judgment regarding future events.
Slide 3: Investment Highlights
3 Investment Highlights Clinical stage biopharma developing innovative drugs to treat life-threatening infectious disease, respiratory disease and oncology Lead compound, cethromycin, a Phase III antibiotic overcomes bacterial resistance in the community Cethromycin met all endpoints in first of two
Slide 4: Deep Clinical Pipeline
4 Lung tissue protectant Initiating Phase I trials in 2008 Anti-melanoma drug Initiating Phase I/II trials in 2007 Inhalation anthrax 100% protective in primate study Novel respiratory antibiotic Completed 1 of 2 pivotal Phase III CAP trials All endpoints met with positive safety results in first tr
Slide 5: Infectious Disease Programs
5 Novel respiratory antibiotic Potential treatment for anthrax and other high-priority biodefense pathogens Cethromycin Infectious Disease Programs
Slide 6: Cethromycin – Novel Respiratory Antibiotic
6 Cethromycin – Novel Respiratory Antibiotic Novel once-a-day oral antibiotic tested in over 5,000 subjects demonstrating strong efficacy and favorable safety profile Potent against broad range of respiratory tract pathogens Overcomes penicillin and macrolide resistance without causing collateral da
Slide 7: Cethromycin: Mechanism of Action
7 Dual, ultra-tight binding increases potency Blocks bacterial protein synthesis Engineered to overcome bacterial resistance Cethromycin: Mechanism of Action Cethromycin binds tightly to two sites on ribosomal RNA
Slide 8: Cethromycin – U.S. RTI Market Potential
8 Cethromycin – U.S. RTI Market Potential CAP affects 6 million patients each year with 10 million physician visits Bronchitis affects 13 million patients per year Sinusitis impacts 31 million patients annually, with 25 million office visits Pediatric RTI market represents 50 million annual prescrip
Slide 9: U.S. Adult Oral Antibiotic Market Share
9 U.S. Adult Oral Antibiotic Market Share 220 Million Prescriptions Total Market is $7 Billion* * IMS Data Resistance and collateral damage driving demand for new therapies Macrolides 24% Other 16% Quinolones 17% Penicillins 43%
Slide 10: Cethromycin Initial Focus: Potential Treatment for CAP
10 Cethromycin Initial Focus: Potential Treatment for CAP
Slide 11: Cethromycin – Potential Treatment for CAP
11 Cethromycin – Potential Treatment for CAP CAP is gold standard for RTI and the 6th leading cause of death in the U.S. 6 million cases of CAP annually in the U.S. with annual spend of $2 billion for antibiotics Clear regulatory pathway to approval in CAP Potent activity against Streptococcus pneum
Slide 12: Macrolides and Penicillins are Losing Effectiveness
12 Macrolides and Penicillins are Losing Effectiveness Resistance is driving demand for new RTI therapies Donald E. Low; Industry Analysis, Antimicrobial Resistance, Mt. Sinai Hospital & University of Toronto, 2000 % Resistance S. Pneumoniae resistance rates approaching 40 – 60% U.S. RTI pathogen re
Slide 13: Fluoroquinolones Causing Collateral Damage
13 Fluoroquinolones Causing Collateral Damage Overuse of fluoroquinolones has caused Increased incidence of clostridium difficile associated disease (CDAD) Class cross resistance Heavy GI side effects and may lead to decreased use of this drug class for RTIs Cethromycin overcomes resistance without
Slide 14: Growing Demand for Antibiotics that Overcome Resistance
14 Growing Demand for Antibiotics that Overcome Resistance without Collateral Damage Resistance in RTIs is a $5 billion economic burden in the U.S.1 Cost of hospitalized CAP patient failing penicillins or macrolides is $15,000 vs. $200 office visit with prescription2 Economic burden for CDAD is over
Slide 15: Cethromycin – Phase III Clinical Trial Design
15 Cethromycin – Phase III Clinical Trial Design Powered to demonstrate clinical cure rate non-inferiority using 95% confidence interval FDA requires demonstration of non-inferiority to current standard of care for CAP trials Cethromycin was dosed 300 mg QD vs. Biaxin® dosed at 250 mg BID for 7 days
Slide 16: Cethromycin – Phase III Efficacy in CAP
16 Cethromycin – Phase III Efficacy in CAP CETHROMYCIN BIAXIN® Statistical Analysis Delta P-Value Endpoint Met Clinical Cure Rate (PPc) 91.5% (205/224) 95.9% (212/221) [-9.1,+0.3] 10% 0.0775 Clinical Cure Rate (mITT) 82.9% (213/257) 88.5% (224/253) [-11.9,+0.6] 15% 0.0769 Radiographic Success Rate (
Slide 17: Cethromycin – Phase III Safety Profile
17 Cethromycin – Phase III Safety Profile Adverse Events Cethromycin 300 mg QD (N=221) Biaxin® 250 mg BID (N=224) Diarrhea 5.0% 4.6% Headache 3.1% 6.5% Nausea 2.7% 3.8% Taste Perversion 11.1% 6.2% Favorable hepatic and cardiac safety profile GI events similar to (or better than) Biaxin® Less than 2%
Slide 18: Global Commercialization Strategy
18 Global Commercialization Strategy Assuming FDA approval, launch in CAP with commercial partner with PCP sales force With commercial partner, co-develop cethromycin for other indications; option to co-promote Expect milestone and royalty based deal structure Engage commercial partner in Europe and
Slide 19: Cethromycin Potential Treatment for Anthrax and Other Biodefense Pathogens
19 Cethromycin Potential Treatment for Anthrax and Other Biodefense Pathogens
Slide 20: Cethromycin – Biodefense Applications
20 Cethromycin – Biodefense Applications Need novel agents with new mechanisms for bioterrorism protection Studies in collaboration with USAMRIID and NIAID Superior potency in vitro vs. approved drugs against more than 30 anthrax strains and other high-priority pathogens Shown to be 100% protective
Slide 21: Cethromycin Milestones: Past and Future
21 Cethromycin Milestones: Past and Future
Slide 22: Milestones Achieved To Date
22 Milestones Achieved To Date Reported positive data for cethromycin as in 1st of 2 pivotal trials in CAP Established manufacturing partnerships for API and drug product Formed National Advisory Board of physician experts to support NDA and commercialization processes Reported positive data from an
Slide 23: Near-term Milestones
23 Near-term Milestones 7 posters and satellite symposium at ICAAC in Chicago Report top-line results from Trial CL-05 4 posters at IDSA in San Diego Q3 ’07 Q4 ’07 • • • Focused on commercial partnership completion and NDA filing
Slide 24: Oncology Programs
24 Oncology Programs Anti-melanoma drug Initiating Phase I/II trials in early 2008 ALS-357
Slide 25: ALS-357 – Targeting Metastatic Melanoma
25 ALS-357 – Targeting Metastatic Melanoma FDA granted Orphan Drug status for topical treatment of metastatic melanoma 55,000 new cases of melanoma cases diagnosed each year1 Unique mechanism: induces mitochondria- mediated apoptosis Demonstrated potent anti-tumor activity against malignant melanoma
Slide 26: Respiratory Programs
26 Lung tissue protectant IND approved; expected to enter Phase I trials in 2008 ALS-886 Respiratory Programs
Slide 27: ALS-886 - Targeting Acute Respiratory Distress (ARDS)
27 ALS-886 - Targeting Acute Respiratory Distress (ARDS) 200,000 ARDS cases per year, 50% mortality No product currently on the market to address disease Inhibits tissue injury in ARDS Strong safety and efficacy profile established IND approved; expected to enter Phase I trial in 2008 O O O O H O O
Slide 28: Corporate Information
28 Corporate Information Beneficial Holder Percent Ownership Common Stock (Fully Diluted) Management 34% Abbott Laboratories 6% Institutions 60% TOTAL 100% Market Nasdaq Ticker ADLS Cash Balance (6/30/07) $13.5M Shares Outstanding (fully diluted) 35.3M Share Price Range (52-week) $1.29-$3.97 Average
Slide 29: Investment Highlights
29 Investment Highlights Developing innovative drugs to treat life-threatening infectious disease, respiratory disease and oncology Lead compound, cethromycin, a Phase III antibiotic overcomes bacterial resistance in the community Cethromycin met all endpoints in first of two pivotal Phase III trial
Advanced Life Sciences Holdings — Investor Presentation (September 2007) on 6ix